indisetron hydrochloride profile

indisetron hydrochloride: an anti-emetic agent, indisetron hydrochloride was developed in Japan; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	178038
SCHEMBL ID	15313306
MeSH ID	M0484399

Synonym
indisetron hcl nisshin
indisetron hydrochloride
n-3389
sinseron
sinseron (tn)
indisetron hydrochloride (jan)
D02632
160472-97-9
n 3389
unii-nbn3hb12dw
nbn3hb12dw ,
1h-indazole-3-carboxamide, n-(3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, dihydrochloride, endo-
1h-indazole-3-carboxamide, n-((7-endo)-3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, dihydrochloride
indisetron hydrochloride [jan]
n-(endo-3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-1h-indazole-3-carboxamide dihydrochloride
indisetron dihydrochloride
SCHEMBL15313306
n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;dihydrochloride
n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;dihydrochloride.
I-175
Q27284778

Excerpt	Reference	Relevance
" No serious adverse events were observed."	( [The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer]. Emoto, M; Hachisuga, T; Kamura, T; Kawarabayashi, T; Kobayashi, H; Kotera, K; Masuzaki, H; Toki, N; Ushijima, K; Wake, N, 2008)	0.64

Excerpt	Relevance	Reference
" We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6)."	( Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. Asaka, M; Kato, K; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Muto, S; Nakatsumi, H; Oba, K; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2012)	0.38

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (25.00)	18.2507
2000's	4 (50.00)	29.6817
2010's	2 (25.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (37.50%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	1 (12.50%)	4.05%
Observational	0 (0.00%)	0.25%
Other	3 (37.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
2-methyl-5-ht 2-methyl-5-HT: M-receptor agonist	2.39	2	0	tryptamines	serotonergic agonist
5-methoxytryptamine 5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.. 5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.	1.99	1	0	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	3.46	1	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.39	2	0	indazole
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.02	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
copper sulfate Copper Sulfate: A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.. copper(II) sulfate : A metal sulfate compound having copper(2+) as the metal ion.	1.99	1	0	metal sulfate	emetic; fertilizer; sensitiser
irinotecan [no description available]	2.02	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
piboserod Serotonin 5-HT4 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT4 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN RECEPTOR AGONISTS.	3.46	1	1
carboplatin [no description available]	3.43	1	1
levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.	3.46	1	1	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite

Condition	Relationship Strength	Studies	Trials
Adverse Drug Event [description not available]	3.43	1	1
Female Genital Neoplasms [description not available]	3.43	1	1
Cancer of Ovary [description not available]	3.43	1	1
Emesis [description not available]	5.25	4	3
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	3.43	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	6.18	4	3
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	3.43	1	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	5.25	4	3
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	3.43	1	1
Cancer of Lung [description not available]	3.43	1	1
Lung Neoplasms Tumors or cancer of the LUNG.	3.43	1	1
Colorectal Cancer [description not available]	3.46	1	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.46	1	1
Benign Neoplasms [description not available]	2.94	1	0
Anticipatory Vomiting [description not available]	2.94	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.94	1	0
Lymph Node Metastasis [description not available]	2.02	1	0
Cancer of Stomach [description not available]	2.02	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	7.02	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.02	1	0

indisetron hydrochloride

Description

Cross-References

Synonyms (21)

Research Excerpts

Toxicity

Dosage Studied

Research

Studies (8)

Market Indicators

Research Demand Index: 12.06

Study Types